U.S. flag An official website of the United States government
  1. Home
  2. Science & Research
  3. About Science & Research at FDA
  4. Ethnicity- and Gender-Related Differences in Alzheimer’s Disease - 01/11/2018 - 01/11/2018
  1. About Science & Research at FDA

Education | Mixed

Event Title
Ethnicity- and Gender-Related Differences in Alzheimer’s Disease
January 11, 2018


Jan. 11, 2018 FDA Grand Rounds Webcast on Ethnicity- and Gender-Related Differences in Alzheimer’s

Thursday, Jan. 11, 2018
12:00 p.m. - 1:00 p.m.


Presented by

Sherry Ferguson, PhD
Research Psychologist
Division of Neurotoxicology
FDA’s National Center for Toxicological Research (NCTR)

Vijayalakshmi Varma, PhD
Research Biologist, NCTR 

Webcast Lecture

Ethnicity- and Gender-Related Differences in Alzheimer’s Disease 

About the Presentation

Better understanding of ethnicity and gender differences involved in the cause and progression of AD could contribute to better drugs and other types of interventions to slow the disease progression. 

Research has shown that minorities and women are particularly vulnerable to Alzheimer’s disease (AD).  Women have a higher incidence of AD at later ages and relative to Caucasians, the threat of AD is even more substantial in the African-American and Hispanic communities. More research into African Americans and other minority populations with AD is crucial to the goals of precision medicine. Studies show the advantage of using different approaches to understanding what is likely to be a complex picture of AD-related ethnicity differences.   

This presentation will discuss research into protein levels in post-mortem African American and Caucasian brain tissue from both genders to explore ethnicity- and gender-related differences. The selected proteins include those thought to be critically involved in AD. Those proteins were examined in samples of the middle temporal gyrus that were matched for age at death since this region is critically involved in language processing and generation and has been shown to be significantly affected by AD. 

About the Presenters

Research psychologist Sherry Ferguson, PhD, has conducted neurotoxicological research since joining FDA’s National Center for Toxicological Research (NCTR) in 1990.  Dr. Ferguson earned a PhD in Physiological Psychology from the University of Wisconsin at Madison.  She is on the editorial board of several scientific journals and is a past president of the Developmental Neurotoxicology Society (formerly, the Neurobehavioral Teratology Society).  She holds adjunct status at the University of Arkansas for Medical Sciences and the University of Arkansas at Little Rock. 

Vijayalakshmi Varma, PhD, joined NCTR’s Division of Systems Biology in 2009 as a research biologist . She earned a PhD in Biochemistry and Cell Biology from Manipal Academy of Higher Education, Manipal University, India. For over 13 years, she has conducted research into metabolic syndrome and its co-morbidities, including obesity, insulin resistance, and obesity-induced inflammation, in clinical translational studies and in disease modeling, using in vitro cell culture and in vivo rodent systems. She leads research efforts to explore the impact of obesity on drug-induced toxicities. 

Requirements to Receive Credit for Each Lecture/Session

Participants must create an account to attest to their attendance and complete the final activity evaluation through the CE Portal here.  The training point of contact will e-mail you with a reminder and instructions to claim credit within 24 hours after each session. Final activity evaluations must be completed within two weeks after the activity, without exception.  

Back to Top